ReviewFrontiers in oncology2021
Relapsed Primary Central Nervous System Lymphoma: Current Advances.
Review in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- The Role of Pretherapeutic Diffusion-Weighted MR Imaging Derived Apparent Diffusion Coefficient in Predicting Clinical Outcomes in Immunocompetent Patients with Primary CNS Lymphoma: A Systematic Review and Meta-Analysis.Asian Pacific journal of cancer prevention : APJCP · 2022Pooled it
- Plasmablast-like lymphoma cells as a distinct subpopulation confer multidrug resistance in PCNSL.Neuro-oncology · 2025Article
- A glaucoma drainage implant functioning as a sanctuary site for vitreoretinal lymphoma.American journal of ophthalmology case reports · 2025Article
- Primary Central Nervous System Lymphomas: A Single-Center Experience.Sisli Etfal Hastanesi tip bulteni · 2025Article
- Novel Therapies for Primary Central Nervous System Lymphomas.Current neurology and neuroscience reports · 2024Review
- Surgical Considerations in Treating Central Nervous System Lymphomas: A Case Series of 11 Patients.Current oncology (Toronto, Ont.) · 2024Article
- Molecular Analysis of Liquid Vitreous Biopsy Reveals Occult Lymphoma Following Cytology-Negative Biopsies of the Brain and Vitreous.Ocular immunology and inflammation · 2024Article
- [A single-center, retrospective analysis of relapse and progression patterns of primary central nervous system lymphoma: can whole brain radiotherapy be replaced?]Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2023Article
- The Current Landscape of Immune Checkpoint Inhibitor Immunotherapy for Primary and Metastatic Brain Tumors.Antibodies (Basel, Switzerland) · 2023Review
- European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL).Neuro-oncology · 2023Article
- Pretreatment diffusion-weighted imaging for prediction of relapsed and refractory primary central nervous system lymphoma.Frontiers in neurology · 2023Article
- Checkpoint inhibition in hematologic malignancies.Frontiers in oncology · 2023Review
- Article
- Epstein-barr Virus Negative Primary Central Nervous System Lymphoma Developed after Treatment of Glioblastoma: A Case Report.NMC case report journal · 2022Article
- Elevated neutrophil-to-lymphocyte ratio as a prognostic factor in primary central nervous system lymphoma.Neuro-oncology advancesArticle
- Use of rituximab, temozolomide, and radiation in recurrent and refractory primary central nervous system lymphoma in the Philippines: a retrospective analysis.Neuro-oncology advancesArticle
- Isolated Ocular Relapse Following Prolonged Remission in Primary Central Nervous System Lymphoma: A Case Report.Journal of investigative medicine high impact case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary central nervous system lymphoma is an invasive malignant lymphoma confined to the central nervous system. Although patients undergoing first-line treatment can achieve complete response, most of them still relapse within two years. Relapsed lymphoma is derived from occult lymphoma cells, and B cell receptor pathway activation and immune escape are the key mechanisms for the pathogenesis of PCNSL. Most relapses are in the central nervous system, a small number of relapses are isolated systemic relapses, and clinical symptoms occur early and vary. Current treatments for relapse include high-dose methotrexate rechallenge and other regimens of chemotherapy, whole-brain radiation therapy, hematopoietic stem-cell transplantation, targeted therapy and immunotherapy, which have become promising treatments. The overall prognosis of relapsed PCNSL is very poor, although it is affected by many factors. This article summarizes the mechanisms, related factors, clinical features, follow-up, treatment and prognosis of relapsed primary central nervous system lymphoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.